Through an exclusive collaboration with Cancer Hope Israel, which specializes in providing a comprehensive check of the effectiveness of chemotherapy and innovative biological medicines, Cannabics will provide its proprietary cannabinoid based compounds to be assessed in their anti-tumor properties.
Commercialization will commence in March 2017, when 10 first patients' liquid biopsies will be tested using this technology. The company plans to make this service available to cancer patients in Canada, Europe and the USA, under local medical cannabis regulations in each country and state, by the end of the year. Itamar Borochov, CEO of Cannabics Pharmaceuticals, says "We are the first company in the world to offer cancer patients personalized cannabinoid anti-tumor diagnostics. We are excited to be pioneers in the nexus of cannabis and personalized cancer treatments".
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
About Cancer Hope Israel
Cancer Hope Israel is a Personalized Oncology Center that represents and provides advanced diagnostics for personalized cancer care. Cancer Hope collaborates with worldwide leaders in cancer diagnostics and medical solutions in order to promote personalized oncology treatment as a standard of care. As part of our vision we strive to bring together oncology specialists with cutting-edge diagnostics, in order to enable the patients the best care.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 17 , 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
For Further Information, please contact:
Cannabics Pharmaceuticals, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-announces-initial-commercialization-of-cannabinoids-based-personalized-diagnostics-for-cancer-patients-300403359.html
SOURCE Cannabics Pharmaceuticals Inc.